PUBLISHER: Azoth Analytics | PRODUCT CODE: 1446328
PUBLISHER: Azoth Analytics | PRODUCT CODE: 1446328
Global Immune Thrombocytopenia Drug Market (2024 Edition): Analysis By Treatment (Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists, Corticosteroids, Others), By Type, By End-User, By Region: Market Insights and Forecast (2019-2029)
Executive Summary
Azoth Analytics has released a research report titled "Global Immune Thrombocytopenia Drug Market (2024 Edition)" which provides a complete analysis of the Global Immune Thrombocytopenia Drug industry in terms of market segmentation By Treatment (Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists, Corticosteroids, Others), By Type (Acute, Chronic), By End-User (Hospitals and Clinics, Specialty Centers, Research and Academic Institutes) for the historical period of 2019-2022, the estimates of 2023 and the forecast period of 2024-2029.
The report analyses the Immune Thrombocytopenia Drug Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, United Kingdom, Germany, France, Spain, China, Japan, South Korea, India). The Global Immune Thrombocytopenia Drug market showcased growth at a CAGR of 21.32% during 2019-2022. The market was valued at USD 3661.45 Million in 2022 which is expected to reach USD 12308.37 Million in 2029. Immune Thrombocytopenia Drug Market is being propelled by rising prevalence of immune thrombocytopenia worldwide is a significant driver of the ITP drug market. Factors such as aging populations, improved disease awareness and diagnosis, and the growing incidence of autoimmune diseases contribute to the increasing burden of ITP, driving the demand for effective treatments.
According to National Centre for Biotechnology Information, Immune thrombocytopenia (ITP) occurs with an incidence rate of 1.6 to 3.9 per 100,000 patient-years, The growing prevalence of ITP expands the market opportunity for pharmaceutical companies and other stakeholders involved in the development, manufacturing, and distribution of ITP drugs. A larger patient population translates to increased market potential, driving investment in research and development, marketing, and sales efforts. Pharmaceutical companies may prioritize ITP drug development initiatives to capitalize on the expanding market opportunity presented by the rising prevalence of the condition.
Also, According to National Organization of Rare Disease, In the United States, the annual incidence of ITP is estimated around 3.3 per 100,000 people.3 In Europe, the annual incidence of ITP among adults is estimated at around 1 to 4 per 100,000 people. The growing prevalence of ITP in the has stimulated research and development efforts in the field of ITP drugs. Pharmaceutical companies in these regions have responded to the growing demand for ITP treatments by developing and marketing drugs to address the needs of patients with this condition across different geographic areas.
Novel drug delivery technologies have enhanced the administration and effectiveness of ITP medications. Long-acting formulations, subcutaneous injections, and oral formulations offer improved convenience, reduced dosing frequency, and enhanced patient adherence compared to traditional intravenous therapies. These advancements in drug delivery technology have improved patient comfort and treatment compliance in ITP management.
Advancements in TPO-RAs have led to the development of new agents with improved efficacy and safety profiles. Second-generation TPO-RAs, such as avatrombopag and lusutrombopag, have demonstrated superior platelet response rates and reduced side effects compared to earlier agents like romiplostim and eltrombopag. These advancements have expanded treatment options for patients with ITP and improved treatment outcomes.
Hospitals and clinics have adopted advanced diagnostic technologies to facilitate accurate and timely diagnosis of ITP. Techniques such as flow cytometry, polymerase chain reaction (PCR), and genetic testing allow for the detection of immune dysregulation, autoantibodies, and underlying genetic predispositions in patients with ITP. Advanced diagnostic technologies enable healthcare providers to differentiate primary ITP from secondary causes of thrombocytopenia, guiding treatment decisions and improving patient outcomes.
Technological advancements drive innovation and progress in the global Immune Thrombocytopenia Drug Market, accelerating drug discovery, development, manufacturing, and clinical practice. These advancements enhance biomarker discovery, high-throughput screening, computational modeling, biopharmaceutical manufacturing, drug delivery systems, and digital health technologies, improving the efficacy, safety, and accessibility of ITP treatments for patients worldwide.
Scope of the Report:
- The report analyses the Immune Thrombocytopenia Drug Market by Value (USD Million).
- The report analyses the Immune Thrombocytopenia Drug Market by Pipeline Scenario.
- The report analyses the Immune Thrombocytopenia Drug Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, United Kingdom, Germany, France, Spain, China, Japan, South Korea, India).
- The report presents the analysis of Immune Thrombocytopenia Drug Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.
- The report analyses the Immune Thrombocytopenia Drug Market by Treatment (Intravenous Immunoglobulins, Thrombopoietin Receptor Agonists, Corticosteroids, Others).
- The report analyses the Immune Thrombocytopenia Drug Market by Type (Acute, Chronic).
- The report analyses the Immune Thrombocytopenia Drug Market by End-User (Hospitals and Clinics, Specialty Centers, Research and Academic Institutes).
- The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented by region, By treatment, by type & by end users.
- Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.
- The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include CSL Behring, Rigel Pharmaceuticals, Novartis, Pfizer, Teva Pharmaceutical, Sanofi, Amgen, Inc., Grifols, Takeda Pharmaceuticals and Intas Pharmaceuticals.
Table of Contents
Table of Content
1. Market Background
- 1.1 Scope and Product Outlook
- 1.2 Executive Summary
- 1.3 Research Methodology
2. Strategic Recommendations
- 2.1 Amplify development of intravenous drugs for chronic application
- 2.2 Escalate collaboration initiative with healthcare provider
3. Global Immune Thrombocytopenia Drug Market: Historic and Forecast
- 3.1 Impact Analysis of Macro Economic Factors on Global Immune Thrombocytopenia Drug Market
- 3.2 Pipeline Scenario
- 3.3 Frequency of adult secondary Immune Thrombocytopenia
- 3.4 Global Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
- 3.5 Degree of Impact of Covid-19 on Immune Thrombocytopenia Drug Market
- 3.6 Global Immune Thrombocytopenia Drug Market Segmentation: By Treatment
- 3.6.1 Global Immune Thrombocytopenia Drug Market, By Treatment Overview
- 3.6.2 Global Immune Thrombocytopenia Drug Market Attractiveness Index, By Treatment Overview
- 3.6.3 Global Immune Thrombocytopenia Drug Market Size, By Intravenous Immunoglobulins, By Value, 2019H-2029F (USD Million & CAGR)
- 3.6.4 Global Immune Thrombocytopenia Drug Market Size, By Thrombopoietin Receptor Agonists, By Value, 2019H-2029F (USD Million & CAGR)
- 3.6.5 Global Immune Thrombocytopenia Drug Market Size, By Corticosteroids, By Value, 2019H-2029F (USD Million & CAGR)
- 3.6.6 Global Immune Thrombocytopenia Drug Market Size, By Others, By Value, 2019H-2029F (USD Million & CAGR)
- 3.7 Global Immune Thrombocytopenia Drug Market Segmentation: By Type
- 3.7.1 Global Immune Thrombocytopenia Drug Market, By Type Overview
- 3.7.2 Global Immune Thrombocytopenia Drug Market Attractiveness Index, By Type Overview
- 3.7.3 Global Immune Thrombocytopenia Drug Market Size, By Acute, By Value, 2019H-2029F (USD Million & CAGR)
- 3.7.4 Global Immune Thrombocytopenia Drug Market Size, By Chronic, By Value, 2019H-2029F (USD Million & CAGR)
- 3.8 Global Immune Thrombocytopenia Drug Market Segmentation: By End-User
- 3.8.1 Global Immune Thrombocytopenia Drug Market, By End-User Overview
- 3.8.2 Global Immune Thrombocytopenia Drug Market Attractiveness Index, By End-User Overview
- 3.8.3 Global Immune Thrombocytopenia Drug Market Size, By Hospitals and Clinics, By Value, 2019H-2029F (USD Million & CAGR)
- 3.8.4 Global Immune Thrombocytopenia Drug Market Size, By Specialty Centers, By Value, 2019H-2029F (USD Million & CAGR)
- 3.8.5 Global Immune Thrombocytopenia Drug Market Size, By Research and Academic Institutes, By Value, 2019H-2029F (USD Million & CAGR)
4. Global Immune Thrombocytopenia Drug Market, Region Analysis
- 4.1 Regional Coverage of the Study
- 4.2 Regional Snapshot
5. Americas Immune Thrombocytopenia Drug Market: Historic and Forecast
- 5.1 Americas Immune Thrombocytopenia Drug Market: Snapshot
- 5.2 Americas Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
- 5.3 Americas Immune Thrombocytopenia Drug Market: Key Factors
- 5.4 Americas Immune Thrombocytopenia Drug Market: Segment Analysis
- 5.5 Americas Immune Thrombocytopenia Drug Market Segmentation: By Treatment
- 5.5.1 Americas Immune Thrombocytopenia Drug Market, By Treatment Overview
- 5.5.2 Americas Immune Thrombocytopenia Drug Market Size, By Intravenous Immunoglobulins, By Value, 2019H-2029F (USD Million & CAGR)
- 5.5.3 Americas Immune Thrombocytopenia Drug Market Size, By Thrombopoietin Receptor Agonists, By Value, 2019H-2029F (USD Million & CAGR)
- 5.5.4 Americas Immune Thrombocytopenia Drug Market Size, By Corticosteroids, By Value, 2019H-2029F (USD Million & CAGR)
- 5.5.5 Americas Immune Thrombocytopenia Drug Market Size, By Others, By Value, 2019H-2029F (USD Million & CAGR)
- 5.6 Americas Immune Thrombocytopenia Drug Market Segmentation: By Type
- 5.6.1 Americas Immune Thrombocytopenia Drug Market, By Type Overview
- 5.6.2 Americas Immune Thrombocytopenia Drug Market Size, By Acute, By Value, 2019H-2029F (USD Million & CAGR)
- 5.6.3 Americas Immune Thrombocytopenia Drug Market Size, By Chronic, By Value, 2019H-2029F (USD Million & CAGR)
- 5.7 Americas Immune Thrombocytopenia Drug Market Segmentation: By End-User
- 5.7.1 Americas Immune Thrombocytopenia Drug Market, By End-User Overview
- 5.2.2 Americas Immune Thrombocytopenia Drug Market Size, By Hospitals and Clinics, By Value, 2019H-2029F (USD Million & CAGR)
- 5.7.3 Americas Immune Thrombocytopenia Drug Market Size, By Specialty Centers, By Value, 2019H-2029F (USD Million & CAGR)
- 5.7.4 Americas Immune Thrombocytopenia Drug Market Size, By Research and Academic Institutes, By Value, 2019H-2029F (USD Million & CAGR)
- 5.8 Americas Immune Thrombocytopenia Drug Market Segmentation: By Country
- 5.8.1 Americas Immune Thrombocytopenia Drug Market, By Country Overview
- 5.8.2 United States Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
- 5.8.2.1 United States Immune Thrombocytopenia Drug Market, By Treatment
- 5.8.2.2 United States Immune Thrombocytopenia Drug Market, By Type
- 5.8.2.3 United States Immune Thrombocytopenia Drug Market, By End-User
- 5.8.3 Canada Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
- 5.8.3.1 Canada Immune Thrombocytopenia Drug Market, By Treatment
- 5.8.3.2 Canada Immune Thrombocytopenia Drug Market, By Type
- 5.8.3.3 Canada Immune Thrombocytopenia Drug Market, By End-User
- 5.10.4 Rest of Americas Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
- 5.10.4.1 Rest of Americas Immune Thrombocytopenia Drug Market, By Treatment
- 5.10.4.2 Rest of Americas Immune Thrombocytopenia Drug Market, By Type
- 5.10.4.3 Rest of Americas Immune Thrombocytopenia Drug Market, By End-User
6. Europe Immune Thrombocytopenia Drug Market: Historic and Forecast
- 6.1 Europe Immune Thrombocytopenia Drug Market: Snapshot
- 6.2 Europe Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
- 6.3 Europe Immune Thrombocytopenia Drug Market: Key Factors
- 6.4 Europe Immune Thrombocytopenia Drug Market: Segment Analysis
- 6.5 Europe Immune Thrombocytopenia Drug Market Segmentation: By Treatment
- 6.5.1 Europe Immune Thrombocytopenia Drug Market, By Treatment Overview
- 6.5.2 Europe Immune Thrombocytopenia Drug Market Size, By Intravenous Immunoglobulins, By Value, 2019H-2029F (USD Million & CAGR)
- 6.5.3 Europe Immune Thrombocytopenia Drug Market Size, By Thrombopoietin Receptor Agonists, By Value, 2019H-2029F (USD Million & CAGR)
- 6.5.4 Europe Immune Thrombocytopenia Drug Market Size, By Corticosteroids, By Value, 2019H-2029F (USD Million & CAGR)
- 6.5.5 Europe Immune Thrombocytopenia Drug Market Size, By Others, By Value, 2019H-2029F (USD Million & CAGR)
- 6.6 Europe Immune Thrombocytopenia Drug Market Segmentation: By Type
- 6.6.1 Europe Immune Thrombocytopenia Drug Market, By Type Overview
- 6.6.2 Europe Immune Thrombocytopenia Drug Market Size, By Acute, By Value, 2019H-2029F (USD Million & CAGR)
- 6.6.3 Europe Immune Thrombocytopenia Drug Market Size, By Chronic, By Value, 2019H-2029F (USD Million & CAGR)
- 6.7 Europe Immune Thrombocytopenia Drug Market Segmentation: By End-User
- 6.7.1 Europe Immune Thrombocytopenia Drug Market, By End-User Overview
- 6.5.2 Europe Immune Thrombocytopenia Drug Market Size, By Hospitals and Clinics, By Value, 2019H-2029F (USD Million & CAGR)
- 6.5.3 Europe Immune Thrombocytopenia Drug Market Size, By Specialty Centers, By Value, 2019H-2029F (USD Million & CAGR)
- 6.5.4 Europe Immune Thrombocytopenia Drug Market Size, By Research and Academic Institutes, By Value, 2019H-2029F (USD Million & CAGR)
- 6.8 Europe Immune Thrombocytopenia Drug Market Segmentation: By Country
- 6.8.1 Europe Immune Thrombocytopenia Drug Market, By Country Overview
- 6.8.2 United Kingdom Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
- 6.8.2.1 United Kingdom Immune Thrombocytopenia Drug Market, By Treatment
- 6.8.2.2 United Kingdom Immune Thrombocytopenia Drug Market, By Type
- 6.8.2.3 United Kingdom Immune Thrombocytopenia Drug Market, By End-User
- 6.8.3 Germany Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
- 6.8.3.1 Germany Immune Thrombocytopenia Drug Market, By Treatment
- 6.8.3.2 Germany Immune Thrombocytopenia Drug Market, By Type
- 6.8.3.3 Germany Immune Thrombocytopenia Drug Market, By End-User
- 6.8.4 France Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
- 6.8.4.1 France Immune Thrombocytopenia Drug Market, By Treatment
- 6.8.4.2 France Immune Thrombocytopenia Drug Market, By Type
- 6.8.4.3 France Immune Thrombocytopenia Drug Market, By End-User
- 6.8.5 Spain Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
- 6.8.5.1 Spain Immune Thrombocytopenia Drug Market, By Treatment
- 6.8.5.2 Spain Immune Thrombocytopenia Drug Market, By Type
- 6.8.5.3 Spain Immune Thrombocytopenia Drug Market, By End-User
- 6.8.6 Rest of Europe Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
- 6.8.6.1 Rest of Europe Immune Thrombocytopenia Drug Market, By Treatment
- 6.8.6.2 Rest of Europe Immune Thrombocytopenia Drug Market, By Type
- 6.8.6.3 Rest of Europe Immune Thrombocytopenia Drug Market, By End-User
7. Asia Pacific Immune Thrombocytopenia Drug Market: Historic and Forecast
- 7.1 Asia Pacific Immune Thrombocytopenia Drug Market: Snapshot
- 7.2 Asia Pacific Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
- 7.3 Asia Pacific Immune Thrombocytopenia Drug Market: Key Factors
- 7.4 Asia Pacific Immune Thrombocytopenia Drug Market: Segment Analysis
- 7.5 Asia Pacific Immune Thrombocytopenia Drug Market Segmentation: By Treatment
- 7.5.1 Asia Pacific Immune Thrombocytopenia Drug Market, By Treatment Overview
- 7.5.2 Asia Pacific Immune Thrombocytopenia Drug Market Size, By Intravenous Immunoglobulins, By Value, 2019H-2029F (USD Million & CAGR)
- 7.5.3 Asia Pacific Immune Thrombocytopenia Drug Market Size, By Thrombopoietin Receptor Agonists, By Value, 2019H-2029F (USD Million & CAGR)
- 7.5.4 Asia Pacific Immune Thrombocytopenia Drug Market Size, By Corticosteroids, By Value, 2019H-2029F (USD Million & CAGR)
- 7.5.5 Asia Pacific Immune Thrombocytopenia Drug Market Size, By Others, By Value, 2019H-2029F (USD Million & CAGR)
- 7.6 Asia Pacific Immune Thrombocytopenia Drug Market Segmentation: By Type
- 7.6.1 Asia Pacific Immune Thrombocytopenia Drug Market, By Type Overview
- 7.6.2 Asia Pacific Immune Thrombocytopenia Drug Market Size, By Acute, By Value, 2019H-2029F (USD Million & CAGR)
- 7.6.3 Asia Pacific Immune Thrombocytopenia Drug Market Size, By Chronic, By Value, 2019H-2029F (USD Million & CAGR)
- 7.7 Asia Pacific Immune Thrombocytopenia Drug Market Segmentation: By End-User
- 7.7.1 Asia Pacific Immune Thrombocytopenia Drug Market, By End-User Overview
- 7.7.2 Asia Pacific Immune Thrombocytopenia Drug Market Size, By Hospitals and Clinics, By Value, 2019H-2029F (USD Million & CAGR)
- 7.7.3 Asia Pacific Immune Thrombocytopenia Drug Market Size, By Specialty Centers, By Value, 2019H-2029F (USD Million & CAGR)
- 7.7.4 Asia Pacific Immune Thrombocytopenia Drug Market Size, By Research and Academic Institutes, By Value, 2019H-2029F (USD Million & CAGR)
- 7.8 Asia Pacific Immune Thrombocytopenia Drug Market Segmentation: By Country
- 7.8.1 Asia Pacific Immune Thrombocytopenia Drug Market, By Country Overview
- 7.8.2 China Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
- 7.8.2.1 China Immune Thrombocytopenia Drug Market, By Treatment
- 7.8.2.2 China Immune Thrombocytopenia Drug Market, By Type
- 7.8.2.3 China Immune Thrombocytopenia Drug Market, By End-User
- 7.8.3 Japan Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
- 7.8.3.1 Japan Immune Thrombocytopenia Drug Market, By Treatment
- 7.8.3.2 Japan Immune Thrombocytopenia Drug Market, By Type
- 7.8.3.3 Japan Immune Thrombocytopenia Drug Market, By End-User
- 7.8.4 South Korea Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
- 7.8.4.1 South Korea Immune Thrombocytopenia Drug Market, By Treatment
- 7.8.4.2 South Korea Immune Thrombocytopenia Drug Market, By Type
- 7.8.4.3 South Korea Immune Thrombocytopenia Drug Market, By End-User
- 7.8.5 India Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
- 7.8.5.1 India Immune Thrombocytopenia Drug Market, By Treatment
- 7.8.5.2 India Immune Thrombocytopenia Drug Market, By Type
- 7.8.5.3 India Immune Thrombocytopenia Drug Market, By End-User
- 7.8.6 Rest of Asia Pacific Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
- 7.8.6.1 Rest of Asia Pacific Immune Thrombocytopenia Drug Market, By Treatment
- 7.8.6.2 Rest of Asia Pacific Immune Thrombocytopenia Drug Market, By Type
- 7.8.6.3 Rest of Asia Pacific Immune Thrombocytopenia Drug Market, By End-User
8. Middle East and Africa Immune Thrombocytopenia Drug Market: Historic and Forecast
- 8.1 Middle East and Africa Immune Thrombocytopenia Drug Market: Snapshot
- 8.2 Middle East and Africa Immune Thrombocytopenia Drug Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
- 8.3 Middle East and Africa Immune Thrombocytopenia Drug Market: Key Factors
- 8.4 Middle East and Africa Immune Thrombocytopenia Drug Market: Segment Analysis
- 8.5 Middle East and Africa Immune Thrombocytopenia Drug Market Segmentation: By Treatment
- 8.5.1 Middle East and Africa Immune Thrombocytopenia Drug Market, By Treatment Overview
- 8.5.2 Middle East and Africa Immune Thrombocytopenia Drug Market Size, By Intravenous Immunoglobulins, By Value, 2019H-2029F (USD Million & CAGR)
- 8.5.3 Middle East and Africa Immune Thrombocytopenia Drug Market, By Thrombopoietin Receptor Agonists, By Value, 2019H-2029F (USD Million & CAGR)
- 8.5.4 Middle East and Africa Immune Thrombocytopenia Drug Market Size, By Corticosteroids, By Value, 2019H-2029F (USD Million & CAGR)
- 8.5.5 Middle East and Africa Immune Thrombocytopenia Drug Market, By Others, By Value, 2019H-2029F (USD Million & CAGR)
- 8.6 Middle East and Africa Immune Thrombocytopenia Drug Market Segmentation: By Type
- 8.6.1 Middle East and Africa Immune Thrombocytopenia Drug Market, By Type Overview
- 8.6.2 Middle East and Africa Immune Thrombocytopenia Drug Market Size, By Acute, By Value, 2019H-2029F (USD Million & CAGR)
- 8.6.3 Middle East and Africa Immune Thrombocytopenia Drug Market Size, By Chronic, By Value, 2019H-2029F (USD Million & CAGR)
- 8.7 Middle East and Africa Immune Thrombocytopenia Drug Market Segmentation: By End-User
- 8.7.1 Middle East and Africa Immune Thrombocytopenia Drug Market, By End-User Overview
- 8.7.2 Middle East and Africa Immune Thrombocytopenia Drug Market Size, By Hospitals and Clinics, By Value, 2019H-2029F (USD Million & CAGR)
- 8.7.3 Middle East and Africa Immune Thrombocytopenia Drug Market Size, By Specialty Centers, By Value, 2019H-2029F (USD Million & CAGR)
- 8.7.4 Middle East and Africa Immune Thrombocytopenia Drug Market Size, By Research and Academic Institutes, By Value, 2019H-2029F (USD Million & CAGR)
9. Market Dynamics
- 9.1 Impact assessment of Market Dynamics on Global Immune Thrombocytopenia Drug Market
- 9.2 Drivers
- 9.3 Restraints
- 9.4 Trends
10. Industry Ecosystem Analysis
- 10.1 Porter Analysis
11. Competitive Positioning
- 11.1 Companies' Product Positioning
- 11.2 Market Share of Leading Companies
- 11.3 Company Profiling
- 11.3.1 CSL Behring
- 11.3.2 Rigel Pharmaceuticals
- 11.4.3 Novartis
- 11.3.4 Pfizer
- 11.3.5 Teva Pharmaceutical
- 11.3.6 Sanofi
- 11.3.7 Amgen, Inc.
- 11.3.8 Grifols
- 11.3.9 Takeda Pharmaceuticals
- 11.3.10 Intas Pharmaceuticals
12. About Us and Disclaimer
List of Figures
List of Figures
- Figure 1: Percentage of secondary ITP by age.
- Figure 2: Global Immune Thrombocytopenia Drug Market Size, By Value, 2019-2022 (USD Million)
- Figure 3: Global Immune Thrombocytopenia Drug Market Size, By Value, 2023-2029 (USD Million)
- Figure 4: Global Immune Thrombocytopenia Drug Market Share, By Treatment, 2022 (%)
- Figure 5: Market Attractiveness Analysis of Global Immune Thrombocytopenia Drug Market, By Treatment (2024-2029)
- Figure 6: Global Immune Thrombocytopenia Drug Market Size, By Intravenous Immunoglobulins, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 7: Global Immune Thrombocytopenia Drug Market Absolute Opportunity, By Intravenous Immunoglobulins, 2019H-2029F (USD Million)
- Figure 8: Global Immune Thrombocytopenia Drug Market Size, By Thrombopoietin Receptor Agonists, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 9: Global Immune Thrombocytopenia Drug Market Absolute Opportunity, By Thrombopoietin Receptor Agonists, 2019H-2029F (USD Million)
- Figure 10: Global Immune Thrombocytopenia Drug Market Size, By Corticosteroids, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 11: Global Immune Thrombocytopenia Drug Market Absolute Opportunity, By Corticosteroids, 2019H-2029F (USD Million)
- Figure 12: Global Immune Thrombocytopenia Drug Market Size, By Others, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 13: Global Immune Thrombocytopenia Drug Market Absolute Opportunity, By Others, 2019H-2029F (USD Million)
- Figure 14: Market Attractiveness Analysis of Global Immune Thrombocytopenia Drug Market, By Type (2024-2029)
- Figure 15: Global Immune Thrombocytopenia Drug Market Size, By Acute, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 16: Global Immune Thrombocytopenia Drug Market Absolute Opportunity, By Acute, 2019H-2029F (USD Million)
- Figure 17: Global Immune Thrombocytopenia Drug Market Size, By Chronic, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 18: Global Immune Thrombocytopenia Drug Market Absolute Opportunity, By Chronic, 2019H-2029F (USD Million)
- Figure 19: Market Attractiveness Analysis of Global Immune Thrombocytopenia Drug Market, By End-User Type (2024-2029)
- Figure 20: Global Immune Thrombocytopenia Drug Market Size, By Hospitals and Clinics, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 21: Global Immune Thrombocytopenia Drug Market Absolute Opportunity, By Hospitals and Clinics, 2019H-2029F (USD Million)
- Figure 22: Global Immune Thrombocytopenia Drug Market Size, By Specialty Centers, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 23: Global Immune Thrombocytopenia Drug Market Absolute Opportunity, By Specialty Centers, 2019H-2029F (USD Million)
- Figure 24: Global Immune Thrombocytopenia Drug Market Size, By Research and Academic Institutes, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 25: Global Immune Thrombocytopenia Drug Market Absolute Opportunity, By Research and Academic Institutes, 2019H-2029F (USD Million)
- Figure 26: Americas Immune Thrombocytopenia Drug Market Size, By Value, 2019H-2029F (USD Million)
- Figure 27: Americas Immune Thrombocytopenia Drug Market Share, By Treatment, 2022 (%)
- Figure 28: Americas Immune Thrombocytopenia Drug Market, By Intravenous Immunoglobulins, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 29: Americas Immune Thrombocytopenia Drug Market, By Thrombopoietin Receptor Agonists, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 30: Americas Immune Thrombocytopenia Drug Market, By Corticosteroids, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 31: Americas Immune Thrombocytopenia Drug Market, By Others, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 32: Americas Immune Thrombocytopenia Drug Market, By Acute, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 33: Americas Immune Thrombocytopenia Drug Market, By Chronic, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 34: Americas Immune Thrombocytopenia Drug Market, By Hospitals and Clinics, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 35: Americas Immune Thrombocytopenia Drug Market, By Specialty Centers, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 36: Americas Immune Thrombocytopenia Drug Market, By Research and Academic Institutes, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 37: United States Immune Thrombocytopenia Drug Market, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 38: United States Immune Thrombocytopenia Drug Market Value, By End-User, 2022 (USD Million)
- Figure 39: United States Immune Thrombocytopenia Drug Market Share, By Treatment, By Value, 2022 (%)
- Figure 40: United States Immune Thrombocytopenia Drug Market Share, By Type, By Value, 2022 (%)
- Figure 41: United States Immune Thrombocytopenia Drug Market Share, By End-User, By Value, 2022 (%)
- Figure 42: Canada Immune Thrombocytopenia Drug Market, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 43: Canada Immune Thrombocytopenia Drug Market Value, By End-User, 2022 (USD Million)
- Figure 44: Canada Immune Thrombocytopenia Drug Market Share, By Treatment, By Value, 2022 (%)
- Figure 45: Canada Immune Thrombocytopenia Drug Market Share, By Type, By Value, 2022 (%)
- Figure 46: Canada Immune Thrombocytopenia Drug Market Share, By End-User, By Value, 2022 (%)
- Figure 47: Rest of Americas Immune Thrombocytopenia Drug Market, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 48: Rest of Americas Immune Thrombocytopenia Drug Market Value, By End-User, 2022 (USD Million)
- Figure 49: Rest of Americas Immune Thrombocytopenia Drug Market Share, By Treatment, By Value, 2022 (%)
- Figure 50: Rest of Americas Immune Thrombocytopenia Drug Market Share, By Type, By Value, 2022 (%)
- Figure 51: Rest of Americas Immune Thrombocytopenia Drug Market Share, By End-User, By Value, 2022 (%)
- Figure 52: Europe Immune Thrombocytopenia Drug Market Size, By Value, 2019H-2029F (USD Million)
- Figure 53: Europe Immune Thrombocytopenia Drug Market Share, By Treatment, 2022 (%)
- Figure 54: Europe Immune Thrombocytopenia Drug Market, By Intravenous Immunoglobulins, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 55: Europe Immune Thrombocytopenia Drug Market, By Thrombopoietin Receptor Agonists, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 56: Europe Immune Thrombocytopenia Drug Market, By Corticosteroids, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 57: Europe Immune Thrombocytopenia Drug Market, By Others, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 58: Europe Immune Thrombocytopenia Drug Market, By Acute, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 59: Europe Immune Thrombocytopenia Drug Market, By Chronic, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 60: Europe Immune Thrombocytopenia Drug Market, By Hospitals and Clinics, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 61: Europe Immune Thrombocytopenia Drug Market, By Specialty Centers, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 62: Europe Immune Thrombocytopenia Drug Market, By Research and Academic Institutes, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 63: United Kingdom Immune Thrombocytopenia Drug Market, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 64: United Kingdom Immune Thrombocytopenia Drug Market Value, By End-User, 2022 (USD Million)
- Figure 65: United Kingdom Immune Thrombocytopenia Drug Market Share, By Treatment, By Value, 2022 (%)
- Figure 66: United Kingdom Immune Thrombocytopenia Drug Market Share, By Type, By Value, 2022 (%)
- Figure 67: United Kingdom Immune Thrombocytopenia Drug Market Share, By End-User, By Value, 2022 (%)
- Figure 68: Germany Immune Thrombocytopenia Drug Market, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 69: Germany Immune Thrombocytopenia Drug Market Value, By End-User, 2022 (USD Million)
- Figure 70: Germany Immune Thrombocytopenia Drug Market Share, By Treatment, By Value, 2022 (%)
- Figure 71: Germany Immune Thrombocytopenia Drug Market Share, By Type, By Value, 2022 (%)
- Figure 72: Germany Immune Thrombocytopenia Drug Market Share, By End-User, By Value, 2022 (%)
- Figure 73: France Immune Thrombocytopenia Drug Market, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 74: France Immune Thrombocytopenia Drug Market Value, By End-User, 2022 (USD Million)
- Figure 75: France Immune Thrombocytopenia Drug Market Share, By Treatment, By Value, 2022 (%)
- Figure 76: France Immune Thrombocytopenia Drug Market Share, By Type, By Value, 2022 (%)
- Figure 77: France Immune Thrombocytopenia Drug Market Share, By End-User, By Value, 2022 (%)
- Figure 78: Spain Immune Thrombocytopenia Drug Market, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 79: Spain Immune Thrombocytopenia Drug Market Value, By End-User, 2022 (USD Million)
- Figure 80: Spain Immune Thrombocytopenia Drug Market Share, By Treatment, By Value, 2022 (%)
- Figure 81: Spain Immune Thrombocytopenia Drug Market Share, By Type, By Value, 2022 (%)
- Figure 82: Spain Immune Thrombocytopenia Drug Market Share, By End-User, By Value, 2022 (%)
- Figure 83: Rest of Europe Immune Thrombocytopenia Drug Market, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 84: Rest of Europe Immune Thrombocytopenia Drug Market Value, By End-User, 2022 (USD Million)
- Figure 85: Rest of Europe Immune Thrombocytopenia Drug Market Share, By Treatment, By Value, 2022 (%)
- Figure 86: Rest of Europe Immune Thrombocytopenia Drug Market Share, By Type, By Value, 2022 (%)
- Figure 87: Rest of Europe Immune Thrombocytopenia Drug Market Share, By End-User, By Value, 2022 (%)
- Figure 88: Asia-Pacific Immune Thrombocytopenia Drug Market Size, By Value, 2019H-2029F (USD Million)
- Figure 89: Asia-Pacific Immune Thrombocytopenia Drug Market Share, By Treatment, 2022 (%)
- Figure 90: Asia-Pacific Immune Thrombocytopenia Drug Market, By Intravenous Immunoglobulins, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 91: Asia-Pacific Immune Thrombocytopenia Drug Market, By Thrombopoietin Receptor Agonists, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 92: Asia-Pacific Immune Thrombocytopenia Drug Market, By Corticosteroids, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 93: Asia-Pacific Immune Thrombocytopenia Drug Market, By Others, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 94: Asia-Pacific Immune Thrombocytopenia Drug Market, By Acute, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 95: Asia-Pacific Immune Thrombocytopenia Drug Market, By Chronic, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 96: Asia-Pacific Immune Thrombocytopenia Drug Market, By Hospitals and Clinics, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 97: Asia-Pacific Immune Thrombocytopenia Drug Market, By Specialty Centers, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 98: Asia-Pacific Immune Thrombocytopenia Drug Market, By Research and Academic Institutes, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 99: China Immune Thrombocytopenia Drug Market, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 100: China Immune Thrombocytopenia Drug Market Value, By End-User, 2022 (USD Million)
- Figure 101: China Immune Thrombocytopenia Drug Market Share, By Treatment, By Value, 2022 (%)
- Figure 102: China Immune Thrombocytopenia Drug Market Share, By Type, By Value, 2022 (%)
- Figure 103: China Immune Thrombocytopenia Drug Market Share, By End-User, By Value, 2022 (%)
- Figure 104: Japan Immune Thrombocytopenia Drug Market, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 105: Japan Immune Thrombocytopenia Drug Market Value, By End-User, 2022 (USD Million)
- Figure 106: Japan Immune Thrombocytopenia Drug Market Share, By Treatment, By Value, 2022 (%)
- Figure 107: Japan Immune Thrombocytopenia Drug Market Share, By Type, By Value, 2022 (%)
- Figure 108: Japan Immune Thrombocytopenia Drug Market Share, By End-User, By Value, 2022 (%)
- Figure 109: South Korea Immune Thrombocytopenia Drug Market, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 110: South Korea Immune Thrombocytopenia Drug Market Value, By End-User, 2022 (USD Million)
- Figure 111: South Korea Immune Thrombocytopenia Drug Market Share, By Treatment, By Value, 2022 (%)
- Figure 112: South Korea Immune Thrombocytopenia Drug Market Share, By Type, By Value, 2022 (%)
- Figure 113: South Korea Immune Thrombocytopenia Drug Market Share, By End-User, By Value, 2022 (%)
- Figure 114: India Immune Thrombocytopenia Drug Market, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 115: India Immune Thrombocytopenia Drug Market Value, By End-User, 2022 (USD Million)
- Figure 116: India Immune Thrombocytopenia Drug Market Share, By Treatment, By Value, 2022 (%)
- Figure 117: India Immune Thrombocytopenia Drug Market Share, By Type, By Value, 2022 (%)
- Figure 118: India Immune Thrombocytopenia Drug Market Share, By End-User, By Value, 2022 (%)
- Figure 119: Rest of Asia-Pacific Immune Thrombocytopenia Drug Market, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 120: Rest of Asia-Pacific Immune Thrombocytopenia Drug Market Value, By End-User, 2022 (USD Million)
- Figure 121: Rest of Asia-Pacific Immune Thrombocytopenia Drug Market Share, By Treatment, By Value, 2022 (%)
- Figure 122: Rest of Asia-Pacific Immune Thrombocytopenia Drug Market Share, By Type, By Value, 2022 (%)
- Figure 123: Rest of Asia-Pacific Immune Thrombocytopenia Drug Market Share, By End-User, By Value, 2022 (%)
- Figure 124: Middle East and Africa Immune Thrombocytopenia Drug Market Size, By Value, 2019H-2029F (USD Million)
- Figure 125: Middle East and Africa Immune Thrombocytopenia Drug Market Share, By Treatment, 2022 (%)
- Figure 126: Middle East and Africa Immune Thrombocytopenia Drug Market, By Intravenous Immunoglobulins, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 127: Middle East and Africa Immune Thrombocytopenia Drug Market, By Thrombopoietin Receptor Agonists, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 128: Middle East and Africa Immune Thrombocytopenia Drug Market, By Corticosteroids, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 129: Middle East and Africa Immune Thrombocytopenia Drug Market, By Others, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 130: Middle East and Africa Immune Thrombocytopenia Drug Market, By Acute, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 131: Middle East and Africa Immune Thrombocytopenia Drug Market, By Chronic, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 132: Middle East and Africa Immune Thrombocytopenia Drug Market, By Hospitals and Clinics, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 133: Middle East and Africa Immune Thrombocytopenia Drug Market, By Specialty Centers, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 134: Middle East and Africa Immune Thrombocytopenia Drug Market, By Research and Academic Institutes, By Value, 2019H-2029F (USD Million & CAGR)
- Figure 135: Global Impact of Drivers and Restraints
- Figure 136: Market Share of Prominent Companies of Immune Thrombocytopenia Drug, 2022 (%)
- Figure 137: CSL Revenue, 2020-2022 (USD Million)
- Figure 138: CSL Revenue, By Business Segments, 2022 (%)
- Figure 139: CSL Revenue, By Geographical Segment, 2022 (%)
- Figure 140: Rigel Pharmaceuticals Revenue, 2020-2022 (USD Million)
- Figure 141: Novartis Revenues, 2020-2022 (USD Million)
- Figure 142: Novartis Revenue, By Business Segments, 2022 (%)
- Figure 143: Novartis Revenue, By Geographical Segments, 2022 (%)
- Figure 144: Pfizer Revenues, 2020-2022 (USD Million)
- Figure 145: Pfizer Revenues, By Business Segments, 2022 (%)
- Figure 146: Pfizer Inc. Revenue, By Geographical Segments, 2022 (%)
- Figure 147: Teva Pharmaceuticals Revenues, 2020-2022 (USD Million)
- Figure 148: Teva Pharmaceuticals Revenue, By Geographical Segments, 2022 (%)
- Figure 149: Sanofi Revenues, 2020-2022 (USD Million)
- Figure 150: Sanofi Revenues, By Geographic Segments, 2022 (%)
- Figure 151: Sanofi Revenue, By Business Segments, 2022 (%)
- Figure 152: Amgen, Inc. Revenues, 2020-2022 (USD Million)
- Figure 153: Amgen, Inc. Revenues, By Geographic Segments, 2022 (%)
- Figure 154: Amgen, Inc. Revenue, By Products, 2022 (%)
- Figure 155: Grifols Revenues, 2020-2022 (USD Million)
- Figure 156: Grifols, By Business Segments, 2022 (%)
- Figure 157: Grifols, By Geographical Segments, 2022 (%)
- Figure 158: Takeda Pharmaceuticals Revenues, 2019-2021 (USD Million)
- Figure 159: Takeda Pharmaceuticals Revenues, By Geographic Segments, 2021 (%)
List of Tables
Table A1: Global Impact of Macro Economic Factors, By Region
Table A2: Immune Thrombocytopenia Drug in Pipeline
Table A3: United States Immune Thrombocytopenia Drug Market, By Treatment, By Value, 2019-2022 (USD Million)
Table A4: United States Immune Thrombocytopenia Drug Market, By Treatment, By Value, 2023-2029 (USD Million)
Table A5: United States Immune Thrombocytopenia Drug Market, By Type, By Value, 2019-2022 (USD Million)
Table A6: United States Immune Thrombocytopenia Drug Market, By Type, By Value, 2023-2029 (USD Million)
Table A7: United States Immune Thrombocytopenia Drug Market, By End-User, By Value, 2019-2022 (USD Million)
Table A8: United States Immune Thrombocytopenia Drug Market, By End-User, By Value, 2023-2029 (USD Million)
Table A9: Canada Immune Thrombocytopenia Drug Market, By Treatment, By Value, 2019-2022 (USD Million)
Table A10: Canada Immune Thrombocytopenia Drug Market, By Treatment, By Value, 2023-2029 (USD Million)
Table A11: Canada Immune Thrombocytopenia Drug Market, By Type, By Value, 2019-2022 (USD Million)
Table A12: Canada Immune Thrombocytopenia Drug Market, By Type, By Value, 2023-2029 (USD Million)
Table A13: Canada Immune Thrombocytopenia Drug Market, By End-User, By Value, 2019-2022 (USD Million)
Table A14: Canada Immune Thrombocytopenia Drug Market, By End-User, By Value, 2023-2029 (USD Million)
Table A15: Rest of Americas Immune Thrombocytopenia Drug Market, By Treatment, By Value, 2019-2022 (USD Million)
Table A16: Rest of Americas Immune Thrombocytopenia Drug Market, By Treatment, By Value, 2023-2029 (USD Million)
Table A17: Rest of Americas Immune Thrombocytopenia Drug Market, By Type, By Value, 2019-2022 (USD Million)
Table A18: Rest of Americas Immune Thrombocytopenia Drug Market, By Type, By Value, 2023-2029 (USD Million)
Table A19: Rest of Americas Immune Thrombocytopenia Drug Market, By End-User, By Value, 2019-2022 (USD Million)
Table A20: Rest of Americas Immune Thrombocytopenia Drug Market, By End-User, By Value, 2023-2029 (USD Million)
Table A21: United Kingdom Immune Thrombocytopenia Drug Market, By Treatment, By Value, 2019-2022 (USD Million)
Table A22: United Kingdom Immune Thrombocytopenia Drug Market, By Treatment, By Value, 2023-2029 (USD Million)
Table A23: United Kingdom Immune Thrombocytopenia Drug Market, By Type, By Value, 2019-2022 (USD Million)
Table A24: United Kingdom Immune Thrombocytopenia Drug Market, By Type, By Value, 2023-2029 (USD Million)
Table A25: United Kingdom Immune Thrombocytopenia Drug Market, By End-User, By Value, 2019-2022 (USD Million)
Table A26: United Kingdom Immune Thrombocytopenia Drug Market, By End-User, By Value, 2023-2029 (USD Million)
Table A27: Germany Immune Thrombocytopenia Drug Market, By Treatment, By Value, 2019-2022 (USD Million)
Table A28: Germany Immune Thrombocytopenia Drug Market, By Treatment, By Value, 2023-2029 (USD Million)
Table A29: Germany Immune Thrombocytopenia Drug Market, By Type, By Value, 2019-2022 (USD Million)
Table A30: Germany Immune Thrombocytopenia Drug Market, By Type, By Value, 2023-2029 (USD Million)
Table A31: Germany Immune Thrombocytopenia Drug Market, By End-User, By Value, 2019-2022 (USD Million)
Table A32: Germany Immune Thrombocytopenia Drug Market, By End-User, By Value, 2023-2029 (USD Million)
Table A33: France Immune Thrombocytopenia Drug Market, By Treatment, By Value, 2019-2022 (USD Million)
Table A34: France Immune Thrombocytopenia Drug Market, By Treatment, By Value, 2023-2029 (USD Million)
Table A35: France Immune Thrombocytopenia Drug Market, By Type, By Value, 2019-2022 (USD Million)
Table A36: France Immune Thrombocytopenia Drug Market, By Type, By Value, 2023-2029 (USD Million)
Table A37: France Immune Thrombocytopenia Drug Market, By End-User, By Value, 2019-2022 (USD Million)
Table A38: France Immune Thrombocytopenia Drug Market, By End-User, By Value, 2023-2029 (USD Million)
Table A39: Spain Immune Thrombocytopenia Drug Market, By Treatment, By Value, 2019-2022 (USD Million)
Table A40: Spain Immune Thrombocytopenia Drug Market, By Treatment, By Value, 2023-2029 (USD Million)
Table A41: Spain Immune Thrombocytopenia Drug Market, By Type, By Value, 2019-2022 (USD Million)
Table A42: Spain Immune Thrombocytopenia Drug Market, By Type, By Value, 2023-2029 (USD Million)
Table A43: Spain Immune Thrombocytopenia Drug Market, By End-User, By Value, 2019-2022 (USD Million)
Table A44: Spain Immune Thrombocytopenia Drug Market, By End-User, By Value, 2023-2029 (USD Million)
Table A45: Rest of Europe Immune Thrombocytopenia Drug Market, By Treatment, By Value, 2019-2022 (USD Million)
Table A46: Rest of Europe Immune Thrombocytopenia Drug Market, By Treatment, By Value, 2023-2029 (USD Million)
Table A47: Rest of Europe Immune Thrombocytopenia Drug Market, By Type, By Value, 2019-2022 (USD Million)
Table A48: Rest of Europe Immune Thrombocytopenia Drug Market, By Type, By Value, 2023-2029 (USD Million)
Table A49: Rest of Europe Immune Thrombocytopenia Drug Market, By End-User, By Value, 2019-2022 (USD Million)
Table A50: Rest of Europe Immune Thrombocytopenia Drug Market, By End-User, By Value, 2023-2029 (USD Million)
Table A51: China Immune Thrombocytopenia Drug Market, By Treatment, By Value, 2019-2022 (USD Million)
Table A52: China Immune Thrombocytopenia Drug Market, By Treatment, By Value, 2023-2029 (USD Million)
Table A53: China Immune Thrombocytopenia Drug Market, By Type, By Value, 2019-2022 (USD Million)
Table A54: China Immune Thrombocytopenia Drug Market, By Type, By Value, 2023-2029 (USD Million)
Table A55: China Immune Thrombocytopenia Drug Market, By End-User, By Value, 2019-2022 (USD Million)
Table A56: China Immune Thrombocytopenia Drug Market, By End-User, By Value, 2023-2029 (USD Million)
Table A57: Japan Immune Thrombocytopenia Drug Market, By Treatment, By Value, 2019-2022 (USD Million)
Table A58: Japan Immune Thrombocytopenia Drug Market, By Treatment, By Value, 2023-2029 (USD Million)
Table A59: Japan Immune Thrombocytopenia Drug Market, By Type, By Value, 2019-2022 (USD Million)
Table A60: Japan Immune Thrombocytopenia Drug Market, By Type, By Value, 2023-2029 (USD Million)
Table A61: Japan Immune Thrombocytopenia Drug Market, By End-User, By Value, 2019-2022 (USD Million)
Table A62: Japan Immune Thrombocytopenia Drug Market, By End-User, By Value, 2023-2029 (USD Million)
Table A63: South Korea Immune Thrombocytopenia Drug Market, By Treatment, By Value, 2019-2022 (USD Million)
Table A64: South Korea Immune Thrombocytopenia Drug Market, By Treatment, By Value, 2023-2029 (USD Million)
Table A65: South Korea Immune Thrombocytopenia Drug Market, By Type, By Value, 2019-2022 (USD Million)
Table A66: South Korea Immune Thrombocytopenia Drug Market, By Type, By Value, 2023-2029 (USD Million)
Table A67: South Korea Immune Thrombocytopenia Drug Market, By End-User, By Value, 2019-2022 (USD Million)
Table A68: South Korea Immune Thrombocytopenia Drug Market, By End-User, By Value, 2023-2029 (USD Million)
Table A69: India Immune Thrombocytopenia Drug Market, By Treatment, By Value, 2019-2022 (USD Million)
Table A70: India Immune Thrombocytopenia Drug Market, By Treatment, By Value, 2023-2029 (USD Million)
Table A71: India Immune Thrombocytopenia Drug Market, By Type, By Value, 2019-2022 (USD Million)
Table A72: India Immune Thrombocytopenia Drug Market, By Type, By Value, 2023-2029 (USD Million)
Table A73: India Immune Thrombocytopenia Drug Market, By End-User, By Value, 2019-2022 (USD Million)
Table A74: India Immune Thrombocytopenia Drug Market, By End-User, By Value, 2023-2029 (USD Million)
Table A75: Rest of Asia-Pacific Immune Thrombocytopenia Drug Market, By Treatment Industry, By Value, 2019-2022 (USD Million)
Table A76: Rest of Asia-Pacific Immune Thrombocytopenia Drug Market, By Treatment Industry, By Value, 2023-2029 (USD Million)
Table A77: Rest of Asia-Pacific Immune Thrombocytopenia Drug Market, By Type, By Value, 2019-2022 (USD Million)
Table A78: Rest of Asia-Pacific Immune Thrombocytopenia Drug Market, By Type, By Value, 2023-2029 (USD Million)
Table A79: Rest of Asia-Pacific Immune Thrombocytopenia Drug Market, By End-User, By Value, 2019-2022 (USD Million)
Table A80: Rest of Asia-Pacific Immune Thrombocytopenia Drug Market, By End-User, By Value, 2023-2029 (USD Million)
Table A81: CSL Key Company Financials, 2020-2022
Table A82: Rigel Pharmaceuticals Key Company Financials, 2020-2022
Table A83: Novartis Key Company Financials, 2020-2022
Table A84: Pfizer Key Financials, 2020-2022
Table A85: Teva Pharmaceuticals Key Company Financials, 2020-2022
Table A86: Sanofi Key Financials, 2020-2022
Table A87: Amgen, Inc. Key Financials, 2020-2022
Table A88: Grifols Key Financials, 2020-2022
Table A89: Takeda Pharmaceuticals Key Financials, 2020-2022
